Daniel Kramer

Immunology and Microbiology · Life Sciences

28h-index2.3kcitations144works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Biosimilars and Bioanalytical Methods(26), Monoclonal and Polyclonal Antibodies Research(17), Wildlife Ecology and Conservation(12), Algal biology and biofuel production(10), Conservation, Biodiversity, and Resource Management(9)

Publications144 total

Anti-drug Antibody Validation Testing and Reporting Harmonization Addendum
The AAPS Journal·2026
Deriving novel atrial fibrillation phenotypes using a tree-based artificial intelligence-enhanced electrocardiography approach
npj Digital Medicine·2025· 1 citedOpen Access
2025 White Paper on Recent Issues in Bioanalysis: Redosing Patients with AAV Gene Therapy; CRS Immunogenicity Risk; Shedding Assays; NHP Studies Immunogenicity; CMC vs Bioanalytical Assays; Artificial Intelligence-Powered Genomic Pipelines for NGS ( <u>PART 3A</u> – Recommendations on Gene, Cell, and Vaccine Therapies Immunogenicity &amp; Technologies; Biotherapeutics &amp; Biosimilars Immunogenicity Assessment &amp; Clinical Relevance <u>PART 3B</u> – Regulatory Agencies’ Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell &amp; Vaccine Therapies)
Bioanalysis·2025Open Access
Abstract 4369720: Outcomes of Stylet-Driven Versus Non-Stylet-Driven Leads for Conduction System Pacing: Insights from the NCDR
Circulation·2025
The spatial ventricular gradient is a non-invasive, vectorcardiographic correlate of cardiac fibrosis
Journal of Interventional Cardiac Electrophysiology·2025
Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform
Frontiers in Immunology·2025· 8 citedOpen Access
Artificial intelligence-enhanced electrocardiography identifies normoglycaemic individuals at high risk of future type 2 diabetes mellitus
European Journal of Preventive Cardiology·2025Open Access
Proceedings of the 15 <sup>th</sup> European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
mAbs·2025· 3 citedOpen Access
PO-07-220 PROCEDURAL OUTCOMES OF SINGLE VERSUS DOUBLE TRANSEPTAL PUNCTURE IN CATHETER ABLATION FOR ATRIAL FIBRILLATION: THE NCDR AFIB ABLATION REGISTRY
Heart Rhythm·2025
PO-05-157 ARTIFICIAL INTELLIGENCE-ENHANCED ELECTROCARDIOGRAPHY IDENTIFIES NORMOGLYCAEMIC INDIVIDUALS AT HIGH RISK OF FUTURE TYPE 2 DIABETES MELLITUS
Heart Rhythm·2025Open Access
Mortality and readmissions after ventricular tachycardia ablation: An analysis of inpatient and outpatient state databases
Heart Rhythm·2025· 3 cited
In-depth characterization and semi-quantification of anti-drug antibodies in clinical samples using specific hybrid IC-LC-MS/MS methods
Analytical Biochemistry·2025· 1 cited
2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation <u>(PART 3A</u> – Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment &amp; Clinical Relevance <u>PART 3B</u> – Regulatory Agencies’ Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell &amp; Vaccine Therapies)
Bioanalysis·2025· 6 citedOpen Access
Assessing the impact of homeowner associations’ pro-environmental codes, covenants, and restrictions on member yards
Landscape and Urban Planning·2025
Promoting the Resilience of Health Care Information Systems—The Day Hospitals Stood Still
JAMA Health Forum·2024· 2 citedOpen Access
Cautionary Note on Data Sharing
Circulation Cardiovascular Quality and Outcomes·2024
Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
mAbs·2024· 3 citedOpen Access
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial
Journal of Diabetes Science and Technology·2024· 3 citedOpen Access
In-Depth Characterization and Semi-Quantification of Anti-Drug Antibodies in Clinical Samples Using Specific Hybrid Ic-Lc-Ms/Ms Methods
SSRN Electronic Journal·2024Open Access
Pharmacokinetic similarity of switching <scp>SAR341402</scp> insulin aspart biosimilar and <scp>NovoLog</scp> insulin aspart versus continuous use of <scp>NovoLog</scp> in adults with type 1 diabetes: The <scp>GEMELLI</scp> X trial
Diabetes Obesity and Metabolism·2023· 3 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Kara Stevens(6), João Pedras-Vasconcelos(5), Anna Fogdell‐Hahn(4), Sebastian Spindeldreher(4), Gerald R. Urquhart(4), Meena Subramanyam(3), Jianguo Liu(3), Heike Enke(3), Arika Ligmann-Zielińska(3), Kendra Spence Cheruvelil(3), Patricia A. Soranno(3), Marc Pallardy(3), Philippe Broët(3), Florian Deisenhammer(3), Susan Richards(3), Lakshmi Amaravadi(3), Charles Hottenstein(3), Jim McNally(3), Robert Nelson(3), Robert A. Montgomery(3)